Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Therapeutics Acquisition Strategy Instil Bio is a biotechnology company focused on identifying and advancing innovative therapeutics. It is evaluating acquisitions, in-licensing transactions, and related opportunities that could provide access to new drug candidates. Portfolio Rebuilding Following the wind-down of prior internal...

Recent company news

TILInstil Bio2026-08-13 21:00 EST

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-05-15 11:00 EST

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

TILInstil Bio2026-03-27 11:00 EST

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

TILInstil Bio2026-01-06 12:00 EST

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

TILInstil Bio2025-11-13 12:00 EST

Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Stock data

Close: 7.58 USD
Market cap: 55M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

Related news

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

Instil Bio